Metformine — a new drug for the prevention and treatment of human malignant tumors
DOI:
https://doi.org/10.25305/unj.60837Keywords:
diabetes, metformin, human malignant tumors, brain tumorsAbstract
Metformin is widely used antidiabetic drug in the world, in last years it’s antitumor features have been revealed. Epidemiological studies show decreasing of cancer incidence at patients, been treated by metformin.
Metformin decreases insulin-resistance and prevents emergence of pancreas cancer. Metformin’s inhibiting influence on cancer cells growth was proved. More over, metformin activates protein-kinase, influencing on cells energetic status that provides antitumor effect.
References
1. Dilman V. Ageing, metabolic immunodepression and carcinogenesis. Mechanisms of Ageing and Development. 1978;8:153-173. [CrossRef] [PubMed]
2. Dilman V. Age-associated elevation of hypothalamic, threshold to feedback control, and its role in development, ageine, and disease. The Lancet. 1971;1(7711):1211-1219. [CrossRef] [PubMed]
3. Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prevention Research. 2010;3(9):1060-1065. [CrossRef] [PubMed]
4. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV, Karkach AS, Romanyukha AA. Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle. 2010;9(1):188-197. [CrossRef] [PubMed]
5. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez J. Metformin and cancer: Doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle. 2010;9(6):1057-1064. [CrossRef] [PubMed]
6. Vazquez-Martin A, Oliveras-Ferraros C, Cufi S, Martin-Castillo B, A. Menendez J. Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells. CMM. 2010;10(7):674-691. [CrossRef]
7. Dilman VM, Anisimov VN. Effect of treatment with phenformin, dyphenylhydantoin or L-DOPA on life span and tumor incidence in C3H/Sn mice. Gerontology. 1980;26:241–245. [PubMed]
8. Anisimov VN. [Effect of buformin and diphenylhydantoin on the life span, estrous function and spontaneous tumor incidence in rats]. Vopr Onkol. 1980;26(6):42-48. Russian. [PubMed]
9. Dilman VM, Bershteĭn LM, Zabezhinskiĭ MA, Aleksandrov VA. [Effect of phenformin on mammary gland tumor induction in rats]. Vopr Onkol. 1974;20(9):94-8. Russian. [PubMed]
10. Anisimov VN, Ostroumova MN, Dilman VM. [Inhibition of blastogenic effect of 7.12-dimethylbenz(a)-anthracene in female rats by buformin, diphenylhydantoin, polypeptide pineal extract and L-DOPA]. Bull. Exp. Biol. Med. 1980;89(6):723–725. Russian.[PubMed]
11. Vinnitskii VB, Iakimenko VA. [Effect of fenformin, L-DOPA and para-chlorophenylalanine on the immunological reactivity and chemical carcinogenesis in BALB/c mice]. Vopr Onkol. 1981;27(6):45-50. Russian. [PubMed]
12. Anisimov VN, Pozharisskiĭ KM, Dilman VM. [Effect of fenformin on the blastomogenic action of 1,2-dimethylhydrazine in rats]. Vopr Onkol. 1980;26(8):54-8. Russian. [PubMed]
13. Saydah S. Abnormal Glucose Tolerance and the Risk of Cancer Death in the United States.American Journal of Epidemiology. 2003;157(12):1092-1100. [CrossRef] [PubMed]
14. Lipscombe L, Goodwin P, Zinman B, McLaughlin J, Hux J. Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Res Treat. 2006;98(3):349-356. [CrossRef] [PubMed]
15. Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan J. Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin. Urology. 2010;76(5):1240-1244. [CrossRef] [PubMed]
16. Sahra I, Laurent K, Loubat A et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27(25):3576-3586. [CrossRef] [PubMed]
17. Liu B, Fan Z, Edgerton S et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8(13):2031-2040. [CrossRef] [PubMed]
18. Dowling R, Goodwin P, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Medicine. 2011;9(1):33. [CrossRef] [PubMed]
19. Belfiore A, Frasca F. IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia. 2008;13(4):381-406. [CrossRef] [PubMed]
20. Frasca F, Pandini G, Sciacca L et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Archives of Physiology and Biochemistry. 2008;114(1):23-37. [CrossRef] [PubMed]
21. Mulligan A, OMalley F, Ennis M, Fantus I, Goodwin P. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat. 2007;106(1):39-47. [CrossRef] [PubMed]
22. Soritau O, Tomuleasa C, Aldea M, Petrushev B, Susman S, Gheban D, Ioani H, Cosis A, Brie I, Irimie A, Kacso G, Florian IS. Metformin plus temozolomide-based chemotherapy as adjuvant treatment for WHO grade III and IV malignant gliomas. J BUON. 2011;16(2):282-289. [PubMed]
23. Ben Sahra I, Le Marchand-Brustel Y, Tanti J, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug?. Molecular Cancer Therapeutics. 2010;9(5):1092-1099. [CrossRef] [PubMed]
24. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I.. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecologic Oncology. 2008;110(2):246-250. [CrossRef] [PubMed]
25. Hirsch H, Iliopoulos D, Tsichlis P, Struhl K Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Research. 2009;69(19):7507-7511. [CrossRef] [PubMed]
26. Zhuang Y, Miskimins WK. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal. 2008;3:18. [CrossRef] [PubMed]
27. Wang L. Metformin induces apoptosis of pancreatic cancer cells. World Journal of Gastroenterology. 2008;14(47):7192–7298. [CrossRef] [PubMed]
28. Vazquez-Martin A, Oliveras-Ferraros C, Menendez J. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle. 2009;8(1):88-96. [CrossRef] [PubMed]
29. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Research. 2009;69(16):6539-6545. [CrossRef]
30. Schneider M, Matsuzaki H, Haorah J et al. Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology. 2001;120(5):1263-1270. [CrossRef] [PubMed]
31. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, Re F, Franceschi C. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Experimental Gerontology. 2005;40(8-9):685-693. [CrossRef] [PubMed]
32. Algire C, Zakikhani M, Blouin M, Shuai J, Pollak M. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocrine Related Cancer. 2008;15(3):833-839. [CrossRef] [PubMed]
33. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Research. 2007;67(14):6745-6752. [CrossRef] [PubMed]
34. Phoenix KN, Vumbaca F, Claffey KP. Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat. 2009 Jan;113(1):101-111. [CrossRef] [PubMed]
35. Rae J, Creighton C, Meck J, Haddad B, Johnson M. MDA-MB-435 cells are derived from M14 Melanoma cells––a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat. 2007;104(1):13-19. [CrossRef] [PubMed]
36. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A. Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiology Biomarkers & Prevention. 2009;18(3):701-705. [CrossRef] [PubMed]
37. Goodwin P, Ligibel J, Stambolic V. Metformin in breast cancer: time for action. Journal of Clinical Oncology. 2009;27(20):3271-3273. [CrossRef] [PubMed]
38. Martin-Castillo B, Dorca J, Vazquez-Martin A et al. Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. Annals of Oncology. 2009;21(1):187-189. [CrossRef]
39. Isakovic A, Harhaji L, Stevanovic D, Markovic Z, Sumarac-Dumanovic M, Starcevic V, Micic D, Trajkovic V. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci. 2007;64(10):1290-1302. [CrossRef] [PubMed]
40. Jung J, Park S, Lee S, Seo M, Trosko J, Kang K. Metformin represses self-renewal of the human breast carcinoma stem cells via inhibition of estrogen receptor-mediated OCT4 expression. PLoS ONE. 2011;6(11):e28068. [CrossRef] [PubMed]
41. Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK, Myers JN. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin Cancer Res. 2012 Jan 1;18(1):290-300. [CrossRef] [PubMed]
42. Tomic T, Botton T, Cerezo M et al. Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. Cell Death Dis. 2011;2(9):199. [CrossRef]
43. Rattan R, Graham R, Maguire J, Giri S, Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity In vivo. Neoplasia. 2011;13(5):483-491. [CrossRef] [PubMed]
44. Micic D, Cvijovic G, Trajkovic V, Duntas L, Polovina S. Metformin: Its emerging role in oncology. HJ. 2011;10(1):5-15. [CrossRef] [PubMed]
45. Memmott R, Mercado J, Maier C, Kawabata S, Fox S, Dennis P. Metformin Prevents Tobacco Carcinogen-Induced Lung Tumorigenesis. Cancer Prevention Research. 2010;3(9):1066-1076. [CrossRef] [PubMed]
46. Antonoff M, DCunha J. Teaching an old drug new tricks: metformin as a targeted therapy for lung cancer. Seminars in Thoracic and Cardiovascular Surgery. 2010;22(3):195-196. [CrossRef] [PubMed]
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2012 Nikolay Lisianyi
This work is licensed under a Creative Commons Attribution 4.0 International License.
Ukrainian Neurosurgical Journal abides by the CREATIVE COMMONS copyright rights and permissions for open access journals.
Authors, who are published in this Journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the Journal under the terms of Creative Commons Attribution License, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this Journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form of which it has been published by the Journal (for example, to upload the work to the online storage of the Journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this Journal is included.
